Immuneering (IMRX) Stock Price, News & Analysis

Company Overview

Immuneering Corporation is a clinical-stage biotechnology company focused on developing medicines for cancer patients with limited treatment options. The company’s research centers on the mitogen-activated protein kinase (MAPK) pathway, a cellular signaling network frequently altered in solid tumors, including cancers driven by RAS mutations.

Immuneering’s lead product candidate is IMM-1-104, an oral therapy designed to provide deep and sustained inhibition of the MAPK pathway while using intermittent exposure to help normal cells recover. The candidate is being evaluated in clinical studies for advanced solid tumors, including pancreatic cancer. The company is also developing IMM-6-415, a next-generation investigational treatment intended for RAS-mutant cancers.

Founded in 2008 and headquartered in Cambridge, Massachusetts, Immuneering became a publicly traded company in 2021. Its programs are being developed through clinical research and collaborations with treatment centers, primarily for patients with advanced cancers in the United States and other regions where its trials are conducted. Benjamin Zeskind, Ph.D., is a co-founder and has served as the company’s chief executive officer.

Key Stats

• Today's Range: $4.02 to $4.15
• 50-Day Range: $4.03 to $5.33
• 52-Week Range: $3.86 to $8.48
• Volume: 588,844 shs
• Average Volume: 687,639 shs
• Market Capitalization: $263.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.71
• Consensus Rating: Buy

Immuneering Stock Analysis - MarketRank™

Immuneering scored higher than 42% of companies evaluated by MarketBeat, and ranked 604th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immuneering has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Immuneering has a consensus price target of $15.71, representing about 286.1% upside from its current price of $4.07.

Amount of Analyst Coverage

Immuneering has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immuneering are expected to decrease in the coming year, from ($1.09) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immuneering is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immuneering is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immuneering has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

28.24% of the float of Immuneering has been sold short.

Short Interest Ratio / Days to Cover

Immuneering has a short interest ratio ("days to cover") of 20.55, which indicates bearish sentiment.

Change versus previous month

Short interest in Immuneering has recently increased by 4.80%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuneering does not currently pay a dividend.

Dividend Growth

Immuneering does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.22

News Sentiment

Immuneering has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immuneering this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for IMRX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immuneering insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMRX
• CIK: 1790340
• Web: www.immuneering.com
• Phone: 617-500-8080
• Fax: N/A
• Employees: 57
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immuneering: $15.71
• High Price Target: $20.00
• Low Price Target: $12.00
• Potential Upside/Downside: +286.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.15%
• Return on Assets: -25.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.47
• Quick Ratio: 19.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 64,700,000
• Free Float: 55,057,000
• Market Cap: $263.33 million
• Optionable: Not Optionable
• Beta: 0.46